Most online drug retailers sell pharmaceuticals without industry authorization or proper security measures, says brand researcher MarkMonitor.
|
Shire looks to beat generic competition for Adderall.
|
But Galvus disappoints when compared with generics.
|
Generic drug makers get to keep 180-day exclusivity when the FDA de-lists patents.
|
Arcoxia is easy on the stomach, but it’s tough on the heart.
|
Pharma giant will spend $100 million on R&D in China.
|
Generic competition with Plavix squashes earnings by 65 percent.
|
Federal court denies a rehearing on Lipitor patent case.
|
Redmond giant is working with biotech firms on collaborative drug discovery.
|
Migraine relief without pain attracts VCs.
|
Red Herring magazine’s bioscience news briefs for the week of May 29, 2006.
|
Agency’s rejection of high-dose insomnia pill rips stock and leaves Pfizer deal in flux.
|
Are VCs betting the farm on one horse?
|
Biotech company gears up for competition by setting up India’s largest biologics facility.
|
Growth is shifting, but the industry is none the poorer for that.
|
Bioscience news briefs for the week of April 10, 2006.
|
Startup Nereus gets $18.3 million to look for new drugs in marine microbes.
|
The race is on to serve world’s largest diabetics population.
|
A study claims Celebrex should not receive preferential treatment over Vioxx.
|
Whether Wyeth’s bid to become more ‘biotech’ works or not, startups will benefit.
|
Page
1
of
3
|